RxDoctor Payments Data

Thaw Sint, MD

Critical Care Medicine · Austin, TXNPI 1891893186

Payments from drug & device makers

$2,493in general payments, 2019–2025

Across 144 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$706
  • Sanofi$444
  • Regeneron Healthcare Solutions, Inc.$418
  • Boehringer Ingelheim$181
  • Jazz Pharmaceuticals Inc.$139
  • Itamar Medical Inc$105
  • plus $501 from 13 others

What the payments were for

  • Food & beverage$2,20989%
  • Education$28411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,493 in reported general payments places this provider in the 75th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$197,702
Medicare patients
590
Services billed
2,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter357$429,767
OfevNintedanib Esylate12$261,023
Dupixent PenDupilumab15$54,081
Breztri AerosphereBudesonide/Glycopyr/Formoterol57$53,461
NucalaMepolizumab13$41,654
Breo ElliptaFluticasone/Vilanterol46$36,117
Spiriva RespimatTiotropium Bromide22$27,265
Fluticasone-SalmeterolFluticasone Propion/Salmeterol89$17,936
Advair HfaFluticasone Propion/Salmeterol19$12,989
Albuterol Sulfate HfaAlbuterol Sulfate370$11,020
SymbicortBudesonide/Formoterol Fumarate24$9,792
Tiotropium Bromide11$8,009
Wixela InhubFluticasone Propion/Salmeterol23$5,586
Varenicline Tartrate15$4,267
Montelukast Sodium175$2,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta$706$507,538416 claims
Boehringer IngelheimOfev, Spiriva Respimat$181$288,28834 claims
AstraZenecaBreztri Aerosphere, Symbicort$72$63,25381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →